Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Structure. 2008 Nov 12;16(11):1689–1701. doi: 10.1016/j.str.2008.09.005

Figure 8. NBD-556 analogue-mediated enhancement of infection of CD4-negative, CCR5-expressing cells by viruses containing mutant HIV-1YU2 envelope glycoproteins.

Figure 8

As described in the Figure 4 legend, the area under the dose-response curve (in arbitrary units) was determined for each compound incubated with the viruses bearing the indicated HIV-1YU2 envelope glycoprotein mutant (or A-MLV envelope glycoproteins). The value for this area was normalized to the value calculated for NBD-556 and the viruses with w.t. YU2 envelope glycoproteins in the same experiment. The numbers reported represent the mean values and standard deviations obtained from at least three independent experiments. The relative enhancement of infection of Cf2Th-CCR5 cells is color-coded as follows: red = 0–0.24; yellow = 0.25–0.7; green = >0.7.